[Progress in the identification of intestinal Pi transport inhibitors].
In 2003, the NKF K/DOQI released new clinical practice guidelines for bone metabolism and disease in chronic kidney disease, respectively. Target level of phosphate and Ca x Pi products are set at relative low levels in the new guidelines. Prescription of a new phosphate binder, severamer hydrochloride, a widely recommended in this quideline. Other approaches that could prove fruitful include inhibition of intestinal and renal phosphate transporters. Inhibition of the sodium-dependent phosphate transporter by a small molecule would be a desirable method to control serum phosphate levels in patients with chronic renal disease or undergoning dialysis. In this review the progress in the identification of such an agent is discussed.
Miyamoto
Kenichi
K
The University of Tokushima Graduate School, Institution of Health Biosciences, Department of molecular Nutrition.
Segawa
Hiroko
H
Ito
Mikiko
M
Kuwahata
Masashi
M
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002908:Chronic Disease; D015195:Drug Design; D017245:Foscarnet / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007674:Kidney Diseases / Q000150:complications; D010693:Phloretin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D050608:Sodium-Phosphate Cotransporter Proteins / Q000037:antagonists & inhibitors*
C466384:2'-phosphophloretin; D000998:Antiviral Agents; D050608:Sodium-Phosphate Cotransporter Proteins; D017245:Foscarnet; D010693:Phloretin